Much has changed at Biogen since George Scangos, a biology professor turned biotech exec, became CEO in 2010. He quickly narrowed the firm’s focus to a few areas, including neurological drugs like the one that became Tecfidera, the blockbuster multiple-sclerosis medication introduced in 2013. With an impressive safety and efficacy record, the pill’s launch has been “phenomenal,” says Evercore ISI biotech analyst Mark Schoenebaum. It has also helped Biogen corner the $15 billion MS medication market and is the primary reason the firm, which introduced its fifth MS drug in August, is expecting 40% revenue growth in 2014. —E.F.